PMS-ROPINIROLE TABLET
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
21-06-2017
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
ROPINIROLE (ROPINIROLE HYDROCHLORIDE)
Inapatikana kutoka:
PHARMASCIENCE INC
ATC kanuni:
N04BC04
INN (Jina la Kimataifa):
ROPINIROLE
Kipimo:
2MG
Dawa fomu:
TABLET
Tungo:
ROPINIROLE (ROPINIROLE HYDROCHLORIDE) 2MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
10/100
Dawa ya aina:
Prescription
Eneo la matibabu:
NONERGOT-DERIVATIVE DOPAMINE RECEPTOR AGONISTS
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0132618004; AHFS:
Idhini hali ya:
APPROVED
Idhini ya tarehe:
2009-07-22
Tabia za bidhaa
PRODUCT MONOGRAPH
PR
PMS-ROPINIROLE
Ropinirole Hydrochloride Tablets, House
0.25 mg, 0.5 mg 1.0 mg, 2.0 mg, 5.0 mg ropinirole
(as ropinirole hydrochloride)
ANTIPARKINSONIAN AGENT / DOPAMINE AGONIST
PHARMASCIENCE INC.
DATE OF REVISION:
6111 Ave. Royalmount, Suite 100
June 12, 2017
Montreal, Quebec
H4P 2T4
www.pharmascience.com
SUBMISSION CONTROL NO: 206310
_pms-ROPINIROLE Product Monograph Page 2 of 52 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
4
CONTRAINDICATIONS
...................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
5
ADVERSE REACTIONS
.................................................................................................
10
DRUG INTERACTIONS
..................................................................................................
21
DOSAGE AND ADMINISTRATION
..............................................................................
23
OVERDOSAGE
................................................................................................................
24
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 25
STORAGE AND STABILITY
.........................................................................................
28
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 28
PART II: SCIENTIFIC INFORMATION
................................................................................
30
PHARMACEUTICAL INFORMATION
.........................................................................
30
CLINICAL TRIALS
......................................................................
Soma hati kamili
